| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
5,660,000 |
| Market
Cap: |
2.49(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4404 - $0.4404 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Graybug Vision is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Co.'s product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are causes of retinal disease. Co.'s second product candidate, GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor developed to provide a controlled release of the active drug to maintain reduced intraocular pressure, for six months or longer after a single injection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
4,000 |
1,435,123 |
1,505,415 |
1,505,415 |
| Total Buy Value |
$15,600 |
$5,248,946 |
$5,493,543 |
$5,493,543 |
| Total People Bought |
1 |
6 |
7 |
7 |
| Total Buy Transactions |
2 |
15 |
58 |
58 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roberts Eric W |
CHIEF BUSINESS OFFICER |
• • • |
2024-04-02 |
4 |
B |
$3.90 |
$12,691 |
I/I |
3,254 |
39,894 |
0.01 |
- |
|
| Roberts Eric W |
CHIEF BUSINESS OFFICER |
• • • |
2024-04-01 |
4 |
B |
$3.90 |
$2,909 |
I/I |
746 |
36,640 |
0.01 |
- |
|
| Roberts Eric W |
CHIEF BUSINESS OFFICER |
• • • |
2024-02-05 |
4 |
A |
$4.27 |
$388,618 |
D/D |
91,086 |
111,373 |
|
- |
|
| Leheny A. Rachel |
CHIEF EXECUTIVE OFFICER |
• • • |
2024-01-23 |
4 |
A |
$4.27 |
$388,618 |
D/D |
91,086 |
109,926 |
|
- |
|
| Wilson Robert N |
|
– • – |
2024-01-23 |
4 |
A |
$4.27 |
$291,462 |
D/D |
68,314 |
250,475 |
|
- |
|
| Sanderling Ventures Management Vii |
10% Owner |
– – • |
2024-01-23 |
4 |
B |
$3.70 |
$1,614,176 |
I/I |
436,028 |
30,292 |
1.5 |
- |
|
| Sanderling Ventures Management Vii |
10% Owner |
– – • |
2024-01-23 |
4 |
B |
$3.70 |
$900,904 |
D/D |
243,356 |
946,744 |
2.45 |
- |
|
| Middleton Fred A |
|
– • • |
2024-01-23 |
4 |
B |
$3.70 |
$2,515,080 |
I/I |
679,384 |
30,292 |
0.01 |
- |
|
| Wilson Robert N |
Director |
– • – |
2023-12-11 |
4 |
B |
$3.30 |
$1,670 |
D/D |
506 |
182,161 |
2.31 |
- |
|
| Leheny A. Rachel |
Chief Executive Officer |
• • • |
2023-11-07 |
4 |
B |
$3.34 |
$6,680 |
D/D |
2,000 |
18,840 |
3.15 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-11-06 |
4 |
B |
$3.12 |
$7,488 |
I/I |
2,400 |
35,894 |
2.56 |
- |
|
| Leheny A. Rachel |
Chief Executive Officer |
• • • |
2023-11-06 |
4 |
B |
$3.12 |
$7,615 |
D/D |
2,440 |
16,840 |
3.15 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-11-03 |
4 |
B |
$2.83 |
$31,846 |
I/I |
11,249 |
33,494 |
2.64 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-11-03 |
4 |
B |
$2.77 |
$10,249 |
D/D |
3,700 |
20,287 |
3.15 |
- |
|
| Hebbar Sudarshan |
Chief Medical Officer |
• – – |
2023-11-03 |
4 |
B |
$2.74 |
$98,600 |
D/D |
36,000 |
46,000 |
2.74 |
- |
|
| Leheny A. Rachel |
Chief Executive Officer |
• • • |
2023-11-03 |
4 |
B |
$2.85 |
$14,250 |
D/D |
5,000 |
14,400 |
3.15 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-11-03 |
4 |
B |
$2.70 |
$15,828 |
I/I |
5,860 |
22,245 |
2.56 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-11-03 |
4 |
B |
$2.80 |
$8,960 |
D/D |
3,200 |
16,587 |
3.15 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-08-29 |
4/A |
B |
$3.02 |
$673 |
I/I |
223 |
5,223 |
2.56 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-08-25 |
4 |
B |
$3.18 |
$2,340 |
I/I |
736 |
5,000 |
2.56 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-08-22 |
4 |
B |
$3.27 |
$2,335 |
I/I |
714 |
4,264 |
2.56 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-08-21 |
4 |
B |
$3.25 |
$5,688 |
I/I |
1,750 |
3,550 |
2.56 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-06-26 |
4 |
B |
$3.70 |
$4,441 |
D/D |
1,200 |
13,387 |
3.15 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-06-26 |
4 |
B |
$3.53 |
$706 |
I/I |
200 |
16,385 |
2.56 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-06-23 |
4 |
B |
$3.35 |
$1,675 |
I/I |
500 |
16,185 |
2.56 |
- |
|
131 Records found
|
|
Page 1 of 6 |
|
|
